Clinical trial Recruiting at 1 site Interventional Ages 18 and up

Adaptive versus continuous subthalamic nucleus deep brain stimulation for people with Parkinson's

Official title: Randomized Controlled Trial Comparing Adaptive Versus Continuous Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease

Run by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · NCT06909045 · Data updated 2026-11-12

This project will try adaptive DBS versus regular continuous DBS in people with Parkinson's who already have Medtronic Percept STN implants to see if one gives more daily ON time without troublesome dyskinesia over six months.

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment130 (estimated)
SponsorAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Academic / other
Locations4 sites (Leuven and 3 other locations)
StatusRecruiting
StartedJanuary 27, 2026
Main results expectedFebruary 1, 2027
Study endsFebruary 1, 2027
Registry record updatedJanuary 29, 2026
Trial IDNCT06909045 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults with idiopathic Parkinson's who already have bilateral Medtronic Percept PC/RC STN electrodes, a reliable beta peak in at least one STN, can recognize ON/OFF motor states, speak Dutch, and can give informed consent.

Probably not a fit

Patients without a Percept device or a detectable beta signal, those with cognitive impairment or dementia, those unable to distinguish motor ON/OFF states, pregnant individuals, or those unable to attend required site visits are unlikely to benefit from participation.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized, multicenter trial compares adaptive deep brain stimulation (aDBS) with standard continuous DBS (cDBS) in people with Parkinson disease who already have bilateral Medtronic Percept PC/RC electrodes targeting the subthalamic nucleus. Participants are programmed to cDBS at the first post-programming visit, then randomized 1:1 to remain on cDBS or switch to aDBS two weeks later, with follow-up visits at three and six months. Patients complete PD home diaries at baseline, two weeks, three months, and six months to measure daily ON time without troublesome dyskinesia, the primary outcome. Study sites include Amsterdam UMC (AMC-UvA), Maastricht UMC+, and UZ Leuven.

Why it matters

Potential benefit: If successful, adaptive DBS could increase daily ON time without troublesome dyskinesia and reduce unnecessary stimulation, improving symptom control and possibly extending device battery life.

How similar studies have gone: Small pilot and crossover studies of aDBS have shown promising reductions in dyskinesia and stimulation time, but larger randomized, longer-duration comparisons remain limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Diagnosis of idiopathic PD based on the UK Brain Bank criteria (Hughes et al. 1992);
* Age older than 18 years;
* Previous implantation of Medtronic PerceptTM PC/RC DBS electrodes bilateral targeting the STN;
* Optimal contact point compatible with aDBS in at least one STN;
* Reliable beta peak in at least one STN;
* Able to provide informed consent and comply with the study protocol;
* Understand the Dutch language.

Exclusion Criteria:

* Legally incompetent adults;
* Patients with ongoing participation in other clinical trials involving neurological interventions;
* Inability to recognize the difference between the motor ON or OFF state;
* Mild cognitive impairment or dementia;
* Pregnancy.

Where it's running

  • Amsterdam UMC
    Amsterdam, Netherlands
    Recruiting
  • UZ Leuven
    Leuven, Belgium
    Not yet recruiting
  • Maastricht UMC+
    Maastricht, Netherlands
    Not yet recruiting
  • HagaZiekenhuis
    The Hague, Netherlands
    Not yet recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.